Latest Posts

The Klein Law Firm Announces a Class Action Filed on Behalf of General Electric Company Shareholders and a Lead Plaintiff Deadline of January 2, 2018

NEW YORK, Nov. 22, 2017 (GLOBE NEWSWIRE) — The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of General Electric Company (NYSE:GE) who purchased shares between July 21, 2017 and October 20, 2017. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws.

In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) the Company’s various operating segments, including its Power segment, were underperforming Company projections, with order drops, excess inventories and increased costs; (ii) in turn, the Company overstated GE’s full year 2017 guidance; and (iii) as a result of the foregoing, General Electric’s public statements were materially false and misleading at all relevant times.

On October 20, 2017, the Company disclosed quarterly results for the third quarter 2017, disclosing earnings per share (“EPS”) of $0.29, falling below estimates of $0.49 per share. The Company also lowered 2017 earnings expectations, lowering EPS to $1.05-$1.10 from $1.60-$1.70. On a conference call to discuss its financial results, CEO John Flannery stated that the Company had been completing a review of its operations and that, “While the company has many areas of strength, it’s also clear from our current results that we need to make some major changes with urgency and a depth of purpose. Our results are unacceptable, to say the least.”

Shareholders have until January 2, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sb/general-electric-company?wire=3.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

/EIN News/ — Primary Logo

Pomerantz Law Firm Announces the Filing of a Class Action against Alkermes plc and Certain Officers – ALKS

NEW YORK, Nov. 22, 2017 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Alkermes plc (“Alkermes” or the “Company”) (NASDAQ:ALKS) and certain of its officers.  The class action, filed in United States District Court, for the Southern District of New York, and docketed under 17-cv-09178, is on behalf of a class consisting of investors who purchased or otherwise acquired Alkermes securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased Alkermes securities between February 24, 2015, and November 3, 2017, both dates inclusive, you have until January 22, 2018, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.  To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and amount of shares purchased. 

[Click here to join this class action]

Alkermes plc is a biopharmaceutical company focused on the development of treatments for central nervous system disorders such as addiction, schizophrenia, depression and diabetes.  The Company’s marketed products include Vivitrol (naltrexone for extended-release injectable suspension), a treatment for alcohol and opioid dependence.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:  (i) Alkermes systemically engaged in deceptive marketing campaigns to influence policymakers to use Vivitrol in addiction treatment programs over more scientifically proven and efficacious alternatives; (ii) the foregoing conduct, when disclosed, would foreseeably subject Alkermes to heightened regulatory and legislative scrutiny; (iii) accordingly, the Company’s revenues derived from Vivitrol during the Class Period were unsustainable; and (iv) as a result of the foregoing, Alkermes shares traded at artificially inflated prices during the Class Period, and class members suffered significant losses and damages.

On June ​11, 2017, The New York Times published an article entitled “Seizing On Opioid Crisis, a Drug Maker Lobbies Hard for its Product.”  The article described Alkermes’ aggressive efforts to market Vivitrol while denigrating the efficacy of other addiction treatments.

On this news, Alkermes’ share price fell $2.19, or 3.55%, to close at $59.47 on June 12, 2017.

On November 6, 2017, U.S. Senator Kamala Harris announced the opening of an investigation into Alkermes’ sales practices for Vivitrol.  Senator Harris specifically stated that the Company “aggressively marketed” its medication, convincing judges and prison officials to use it rather than more proven addiction-treatment products, and spent hundreds of thousands of dollars lobbying policymakers.  According to Harris, Alkermes promoted Vivitrol by using a “speaker’s bureau composed of doctors paid to promote the drug.”

On this news, Alkermes’ share price fell $2.23, or 4.37%, to close at $48.76 on November 6, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com 

/EIN News/ —

GENOCEA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 In Genocea Biosciences, Inc. To Contact The Firm

/EIN News/ — NEW YORK, Nov. 22, 2017 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Genocea Biosciences, Inc. (“Genocea” or the “Company”) (NASDAQ:GNCA) of the January 2, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Genocea securities between May 5, 2017 and September 25, 2017 and would like to discuss your legal rights, click here: www.faruqilaw.com/GNCA. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of all those who purchased Genocea securities between May 5, 2017 and September 25, 2017 (the “Class Period”).  The case, Emerson v. Genocea Biosciences, Inc., No. 1:17-cv-12137 was filed on October 31, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failed to disclose that: (i) the Company’s finances were insufficient to support Phase 3 trials of the Company’s lead product candidate GEN-003; (ii) accordingly, Genocea had overstated the prospects for GEN-003; and (iii) as a result of the foregoing, Genocea’s public statements were materially false and misleading at all relevant times.

Specifically, on September 25, 2017, after market close, Genocea disclosed that it was halting spending and activities on GEN-003 and exploring strategic alternatives for the drug. Additionally, the Company announced that it was cutting 40% of its workforce.

On this news, Genocea’s share price fell from $5.33 per share on September 25, 2017 to a closing price of $1.25 on September 26, 2017—a $4.08 or a 76.55% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding Genocea’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Primary Logo

OVASCIENCE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In OvaScience, Inc. To Contact The Firm

/EIN News/ — NEW YORK, Nov. 22, 2017 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in OvaScience, Inc. (“OvaScience” or the “Company”) (NASDAQ:OVAS) of the January 22, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in OvaScience stock or options in the Company’s Secondary Offering on or about January 8, 2015 (the “Secondary Offering”) and would like to discuss your legal rights, click here: www.faruqilaw.com/OVASThere is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of all those who purchased OvaScience common stock directly in the Company’s Secondary Offering.  The case, Westmoreland County Employee Retirement System v. OvaScience, Inc. et al, No. 1.17-cv-12312 was filed on November 22, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by negligently issuing untrue statements of material facts and omitting to state material facts required to be stated from the Registration Statement, as amended, the January 6, 2015 Preliminary Prospectus Supplement, the January 8, 2015 Prospectus Supplement, and all documents incorporated therein (the “Offering Materials”).

Specifically, the lawsuit alleges that the Offering Materials contained misleading statements about and/or failed to disclose that: (i) the science behind the Company’s Autologous Germline Mitochondrial Energy Transfer (“AUGMENT”) treatment was untested and in doubt; (ii) the patients that had received the Company’s AUGMENT procedure in 2014 did not achieve a pregnancy success rate that was significantly higher than the rate achieved without the AUGMENT procedure; (iii) the Company had not chosen to undertake its studies outside of the United States, but was forced to as it did not want to meet rigorous federal regulations; and (iv) the Company was far from being profitable.

Since the Company’s Secondary Offering, OvaScience’s share price has declined over 95%.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding OvaScience’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Primary Logo

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alkermes plc To Contact The Firm

/EIN News/ — NEW YORK, Nov. 22, 2017 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc (“Alkermes” or the “Company”) (NASDAQ:ALKS) of the January 22, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Alkermes stock or options between February 24, 2015 and November 3, 2017 and would like to discuss your legal rights, click here: www.faruqilaw.com/ALKS.  There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Alkermes securities between February 24, 2015 and November 3, 2017 (the “Class Period”).  The case, Gagnon v. Alkermes plc et al, No. 1:17-cv-09178 was filed on November 22, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) the Company engaged in deceptive marketing campaigns to influence policymakers to use Vivitrol, a treatment for alcohol and opioid dependence, in addiction treatment programs over more scientifically proven and efficacious alternatives; (ii) the aforementioned conduct, when disclosed, would subject the Company to heightened regulatory and legislative scrutiny; (iii) consequently, the Company’s revenues derived from Vivitrol during the Class Period were unsustainable; and (iv) as a result, Alkermes shares traded at artificially inflated prices during the Class Period.

Specifically, on June 11, 2017, The New York Times published an article describing the Company’s aggressive efforts to market Vivitrol while denigrating the efficacy of other addiction treatments.  On this news, Alkermes’ share price fell from $61.66 per share on June 9, 2017 to a closing price of $59.47 on June 12, 2017—a $2.19 or a 3.55% drop.

Then, on November 6, 2017, U.S. Senator Kamala Harris (“Senator Harris”) announced the opening of an investigation into Alkermes’ sales practices for Vivitrol.  Senator Harris stated that the Company “aggressively marketed” its medication, convincing judges and prison officials to use it rather than more proven addiction-treatment products, and spent hundreds of thousands of dollars lobbying policymakers.  Furthermore, according to Senator Harris, Alkermes promoted Vivitrol by using a “speaker’s bureau composed of doctors paid to promote the drug.”  On this news, Alkermes’ share price fell from $50.99 per share on November 3, 2017 to a closing price of $48.76 on November 6, 2017—a $2.23 or a 4.37% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding Alkermes’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Primary Logo

Recipients of VA Disability, Retirees to Receive Pay Increase

Tampa, FL (Law Firm Newswire) November 21, 2017 – Military retirees and persons who are recipients of disability checks and other kinds of pay from the Department of Veterans Affairs will receive a two percent pay increase in their monthly paycheck in 2018. Since 2012, this marks the largest cost of living (COLA) increase, which could be as high as $310 per month for those at the highest level of the retirement pay charts.

Because of the rise in pay, the average military retirement check for an E-7 with 20 years of service will rise by $45 per month. An O-5 who spent the same amount of time in the military will experience an increase in the amount of $85 per month. Disabled veterans will also see an increase. The average disability check will rise by about $3 per month for those who have a 10 percent rating. And it will rise by $58 for those with a 100 percent rating.

Florida veterans attorney David W. Magann says, “It is only fitting that military retirees and recipients of VA disability should benefit from an increase in their pay as a result of a rise in COLA.”

Furthermore, beneficiaries of Survivor Benefit Planning and those who receive Dependency and Indemnity Compensation (DIC) will see an increase in payments. Moreover, civil service retirees will have a two percent hike in their checks. Those who receive Social Security will see an extra $25 per month.

This year marks the largest COLA increase in years. There is a COLA increase every year in the majority of government payments. The increase is based on the Consumer Price Index (CPI), which makes certain that payments keep pace with inflation.

The reason for the surge in COLA this year is the dramatic rise in the cost of gasoline because of Hurricane Harvey. Following Hurricane Harvey, the price of gasoline rose considerably by about 15 percent. According to the government, gasoline comprises approximately four percent of the average monthly spending in a household.

The COLA impacts benefits for over 70 million residents in the United States, including those who receive Social Security, disabled veterans, federal retirees and retired military members. That is approximately 20 percent of Americans.

Last year, COLA rose by 0.3 percent, and in 2015, there was no change in the payments for retirees. However, Congress has not yet determined the pay raise that troops currently serving in the military will receive in 2018. The Senate passed a proposal that requires a 2.1 percent increase, as does a recommendation by the White House. The House passed a measure that would yield a 2.3 percent increase for troops. Legislators have begun negotiations on the proposed plans.

David W. Magann, P.A.
Main Office:
156 W. Robertson St.
Brandon, FL 33511
Call: (813) 657-9175

Tampa Office:
4012 Gunn Highway #165
Tampa, Florida 33618


View Larger Map

See other news sources publishing this article. BETA |

The Klein Law Firm Announces a Class Action Filed on Behalf of Genocea Biosciences, Inc. Shareholders and a Lead Plaintiff Deadline of January 2, 2018

NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) — The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Genocea Biosciences, Inc. (NASDAQ:GNCA) who purchased shares between May 5, 2017 and September 25, 2017. The action, which was filed in the U.S. District Court for the District of Massachusetts, alleges that the Company violated federal securities laws.

In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) the Company’s finances were insufficient to support Phase 3 trials of GEN-003; (ii) accordingly, Genocea had overstated the prospects for GEN-003; and (iii) as a result of the foregoing, Genocea’s public statements were materially false and misleading at all relevant times.

On September 25, 2017, Genocea disclosed that it was halting spending and activities on GEN-003 and exploring strategic alternatives for the drug.   The Company also announced that it was cutting 40% of its workforce.

Shareholders have until January 2, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sb/genocea-biosciences-inc?wire=3.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com 

/EIN News/ —

The Klein Law Firm Notifies Investors of a Class Action Filed on Behalf of Novan, Inc. Shareholders and a Lead Plaintiff Deadline of January 2, 2018 (NOVN)

NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) — The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Novan, Inc. (NASDAQ:NOVN) who purchased shares (1) pursuant and/or traceable to Novan’s IPO on or about September 26, 2016 or (2) between September 26, 2016 and January 26, 2017. The action, which was filed in the USDC for the Middle District of North Carolina, alleges that the Company violated federal securities laws.

In particular, the complaint alleges the Company made materially false and/or misleading statements in its Registration Statement and Prospectus for the IPO, and made false statements throughout the class period. In particular, among other allegations, the complaint alleges that the Company repeatedly falsely stated that two Phase 3 clinical trials for the treatment SB204 were identical and omitted specific facts as to why the two critical trials were, in fact, not identical; as a result of these false statements, the Company’s outlook and expected financial performance were not accurately represented.

Shareholders have until January 2, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sbm/novan-inc?wire=3.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com 

/EIN News/ —

The Klein Law Firm Reminds Shareholders of a Class Action Filed on Behalf of Intercept Pharmaceuticals, Inc. Shareholders and a Lead Plaintiff Deadline of November 27, 2017

NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) — The Klein Law Firm reminders shareholders that a class action complaint has been filed on behalf of shareholders of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) who purchased shares between May 31, 2016 and September 20, 2017. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws.

In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) the Company’s lead product candidate, Ocaliva, entailed undisclosed safety risks, including death, to patients suffering from primary biliary cholangitis; and (ii) as a result of the foregoing, Intercept’s public statements were materially false and misleading at all relevant times. On September 12, 2017, Intercept issued a letter warning physicians against overdosing patients with Ocaliva, advising them that the drug has been tied to liver injuries and death among patients suffering from PBC. On September 21, 2017, the FDA issued a safety announcement warning doctors after reports of multiple deaths linked to the drug.

Shareholders have until November 27, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sb/intercept-pharmaceuticals-inc?wire=3.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

/EIN News/ —

Arizona Law Offices of Lerner and Rowe Host Fourth Semi-Annual 25 Days of Giving Contest

25 Days of Giving 2017

Lerner and Rowe celebrates the season of giving by granting Christmas and Hanukkah wishes during their fourth semi-annual 25 Days of Giving Contest.

Our 25 Days of Giving contest is one of the most enjoyable and high-impact ways for our law firm to give back and make a difference within local communities. ”

— Kevin Rowe, ESQ.

PHOENIX, AZ, UNITED STATES, November 20, 2017 /EINPresswire.com/ — The Arizona law offices of Lerner and Rowe are granting Christmas and Hanukkah wishes during their fourth semi-annual 25 Days of Giving Contest. Starting November 25, 2017, fans of Lerner and Rowe’s Facebook page are asked to leave a comment stating their holiday wish (up to $500 in value) and then share that wish with their family and friends for a chance to win. One lucky winner is then announced each day of the contest through December 19, 2017. Previous prizes have included new tires, washing machine, refrigerator, bunk beds with mattresses, a drum set, a car seat, gift card to help pay for oral surgery and much more.

“This will be the fourth year for our 25 Days of Giving Contest. It is it still one of the most enjoyable and high-impact ways for our law firm to give back and make a difference within local communities,” said attorney Kevin Rowe.

For more information about Lerner and Rowe’s 25 Days of Giving, please contact Cindy Ernst at (602) 977-1900, or visit the official contest page at LernerAndRowe.com/25-Days-of-Giving.

More about Lerner and Rowe

For additional information about Lerner and Rowe’s Phoenix personal injury attorneys call (602) 977-1900. To learn more about the criminal defense and bankruptcy legal services offered by their partner law firm Lerner and Rowe Law Group, visit lernerandrowelawgroup.com or call (602) 667-7777. Need help filing an application or appeal for Social Security benefits? Contact the law firms other legal partners at Social Security Disability Advocates by calling (602) 952-3200 or online at socialsecuritydisabilityadvocatesusa.com.

To connect with the law firm socially, follow Lerner and Rowe on Twitter, or become a fan of their Facebook page. Also visit lernerandrowegivesback.com to learn more about the community services that the lawyers and legal support team of Lerner and Rowe actively support.

###

Kevin Rowe, ESQ.
Lerner and Rowe, P.C.
(602) 977-1900
email us here